LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

22.1 2.22

Buy Sell

Overview

Share price change

24h

Current

Min

21.3

Max

22.26

Key metrics
By Trading Economics
Income	-270M 3.6M
Sales	-16M 268M
P/E Sector Avg	9.864 51.415
EPS	0.02
Profit margin	1.357
Employees	796
EBITDA	-31M -4.6M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+50.87% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-66M 3.7B
Previous open	19.88
Previous close	22.1

News Sentiment

By Acuity

15%

85%

28 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

14.845 / N/A Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 May 2026, 22:54 UTC

Earnings

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 May 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 May 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 May 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 May 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 May 2026, 23:17 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 May 2026, 23:16 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 May 2026, 23:15 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 May 2026, 23:14 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 May 2026, 23:02 UTC

Market Talk

Earnings

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 May 2026, 22:59 UTC

Market Talk

Earnings

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 May 2026, 22:24 UTC

Earnings

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 May 2026, 22:23 UTC

Earnings

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 May 2026, 22:23 UTC

Earnings

Xero FY International Revenue Growth 47%>XRO.AU

13 May 2026, 22:22 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 May 2026, 22:19 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 May 2026, 22:19 UTC

Earnings

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 May 2026, 22:18 UTC

Earnings

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 May 2026, 22:16 UTC

Earnings

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 May 2026, 22:15 UTC

Earnings

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 May 2026, 22:15 UTC

Earnings

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 May 2026, 22:13 UTC

Earnings

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 May 2026, 22:12 UTC

Earnings

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 May 2026, 22:11 UTC

Earnings

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 May 2026, 22:11 UTC

Earnings

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 May 2026, 22:10 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

13 May 2026, 22:10 UTC

Earnings

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 May 2026, 22:09 UTC

Earnings

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 May 2026, 22:00 UTC

Earnings

Cisco to Shed Jobs for All-In AI Push -- Update

13 May 2026, 21:11 UTC

Earnings

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

50.87% upside

12 Months Forecast

Average 32.77 USD 50.87%

High 38 USD

Low 24 USD

Based on 15 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

14.845 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

28 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.